PapersFlow Research Brief
Vascular Anomalies and Treatments
Research Guide
What is Vascular Anomalies and Treatments?
Vascular anomalies and treatments refer to the diagnosis and management of hereditary hemorrhagic telangiectasia (HHT), a genetic disorder characterized by vascular malformations including telangiectasias and arteriovenous malformations affecting the nose, lungs, liver, and other organs.
The field encompasses 27,479 papers on genetics, pulmonary arteriovenous malformations, embolization, epistaxis, liver involvement, SMAD4 mutations, and related vascular anomalies. Shovlin et al. (2000) established diagnostic criteria for HHT based on epistaxis, telangiectasia, and family history, with visceral arteriovenous malformations as a key feature. Management strategies address complications like pulmonary hypertension, which Simonneau et al. (2018) redefined hemodynamically as mean pulmonary arterial pressure ≥25 mmHg.
Topic Hierarchy
Research Sub-Topics
Hereditary Hemorrhagic Telangiectasia Genetics
HHT genetics research identifies ENG, ACVRL1, and SMAD4 mutations causing vascular malformations. Studies characterize genotype-phenotype correlations, modifier genes, and develop genetic counseling guidelines.
Pulmonary Arteriovenous Malformations in HHT
PAVM research focuses on prevalence, natural history, and paradoxical emboli risks in HHT patients. Studies optimize screening echocardiography and embolization timing to prevent stroke and brain abscess.
HHT Epistaxis Management
Epistaxis studies evaluate laser ablation, septodermoplasty, and medical therapies (bevacizumab, tranexamic acid) for recurrent nosebleeds. Research develops quality-of-life metrics and treatment algorithms.
HHT Liver Vascular Malformations
Liver involvement research characterizes high-output heart failure, biliary disease, and portal hypertension from AVMs. Studies evaluate bevacizumab therapy and liver transplant candidacy criteria.
HHT Diagnostic Criteria
Diagnostic criteria research refines Curacao criteria using genetic testing and improves sensitivity for young/atypical cases. Studies validate non-Osler family screening protocols and population prevalence estimates.
Why It Matters
Vascular anomalies in HHT lead to serious consequences such as recurrent epistaxis, pulmonary arteriovenous malformations causing hypoxemia, and liver involvement risking high-output heart failure. Shovlin et al. (2000) note that delayed diagnosis results in visceral arteriovenous malformations, which embolization treats to prevent complications. Bosentan therapy, as shown by Rubin et al. (2002) in pulmonary arterial hypertension patients, improves hemodynamics at 125 mg twice daily, offering a targeted treatment for associated vascular pressures. In France, Humbert et al. (2006) registry data reveal late detection with severe functional compromise in most patients, underscoring the need for early screening using Curacao criteria from Shovlin et al. (2000). These interventions reduce morbidity in affected families.
Reading Guide
Where to Start
"Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)" by Shovlin et al. (2000), as it provides foundational Curacao criteria essential for recognizing HHT and its vascular anomalies before advancing to treatments.
Key Papers Explained
Shovlin et al. (2000) establish HHT diagnosis via Curacao criteria, enabling identification of patients at risk for complications like pulmonary arteriovenous malformations. Simonneau et al. (2018) and Simonneau et al. (2009) update pulmonary hypertension definitions and classifications, directly relevant to HHT lung involvement. Rubin et al. (2002) demonstrate bosentan efficacy for associated pulmonary arterial hypertension, while Humbert et al. (2006) quantify late diagnosis severity in real-world registries.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research focuses on genetics like SMAD4 mutations and management of epistaxis, embolization, and liver involvement, as per the 27,479 papers. No recent preprints or news available, so frontiers remain in refining criteria from Shovlin et al. (2000) and applying PH therapies from Simonneau et al. (2018).
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Haemodynamic definitions and updated clinical classification o... | 2018 | European Respiratory J... | 3.7K | ✓ |
| 2 | Bosentan Therapy for Pulmonary Arterial Hypertension | 2002 | New England Journal of... | 2.7K | ✓ |
| 3 | ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension | 2009 | Journal of the America... | 2.3K | ✕ |
| 4 | Updated Clinical Classification of Pulmonary Hypertension | 2009 | Journal of the America... | 2.1K | ✕ |
| 5 | Pulmonary Arterial Hypertension in France | 2006 | American Journal of Re... | 2.0K | ✕ |
| 6 | Clinical classification of pulmonary hypertension | 2004 | Journal of the America... | 1.9K | ✓ |
| 7 | Diagnostic criteria for hereditary hemorrhagic telangiectasia ... | 2000 | American Journal of Me... | 1.7K | ✕ |
| 8 | Cellular and molecular pathobiology of pulmonary arterial hype... | 2004 | Journal of the America... | 1.5K | ✕ |
| 9 | Predicting Survival in Pulmonary Arterial Hypertension | 2010 | Circulation | 1.5K | ✓ |
| 10 | DISSECTING ANEURYSM OF THE AORTA | 1958 | Medicine | 1.5K | ✕ |
Frequently Asked Questions
What are the diagnostic criteria for hereditary hemorrhagic telangiectasia?
The Curacao criteria include spontaneous recurrent epistaxis, multiple telangiectasias at characteristic sites, visceral arteriovenous malformations, and family history of HHT. Shovlin et al. (2000) define definite HHT with three or more criteria, possible with two, and unlikely with fewer than two. These enable recognition beyond the classical triad.
How is pulmonary hypertension classified in relation to vascular anomalies?
Simoneneau et al. (2018) updated the hemodynamic definition to mean pulmonary arterial pressure ≥25 mmHg by right heart catheterization. Simonneau et al. (2009) provide clinical classification into five groups, including heritable forms linked to HHT. This guides management of complications from pulmonary arteriovenous malformations.
What treatments are used for pulmonary arterial hypertension in HHT patients?
Bosentan, an endothelin-receptor antagonist, at 125 mg twice daily improves outcomes in pulmonary arterial hypertension. Rubin et al. (2002) demonstrated its efficacy and tolerability. Embolization targets pulmonary arteriovenous malformations directly.
Why is HHT often diagnosed late?
HHT presents variably, with serious visceral lesions in many cases before classical signs. Shovlin et al. (2000) highlight difficulties in diagnosis without the full triad. Humbert et al. (2006) registry shows most patients have severe compromise at detection.
What role do genetics play in vascular anomalies of HHT?
HHT arises from mutations causing vascular malformations, including SMAD4 variants linked to combined syndromes. The field covers genetics alongside malformations in lungs and liver. Diagnostic criteria incorporate family history as a core element per Shovlin et al. (2000).
Open Research Questions
- ? How can screening protocols be optimized to detect visceral arteriovenous malformations earlier in HHT patients?
- ? What are the long-term outcomes of embolization for pulmonary arteriovenous malformations in HHT?
- ? How do SMAD4 mutations influence liver involvement and treatment responses in HHT?
- ? What factors best predict survival in HHT patients with pulmonary hypertension?
- ? How do updated pulmonary hypertension classifications impact HHT management strategies?
Recent Trends
The field includes 27,479 works with no specified 5-year growth rate.
Humbert et al. registry underscores persistent late detection of pulmonary arterial hypertension linked to HHT. No recent preprints or news reported.
2006Research Vascular Anomalies and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Vascular Anomalies and Treatments with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers